Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cue Biopharma ( (CUE) ) is now available.
Cue Biopharma, Inc., a Nasdaq-listed immunotherapy-focused biotechnology company, moved to adjust its capital structure while maintaining its existing authorized share count and par value, reflecting efforts to preserve financial and listing flexibility. The company’s common stock, options, warrants and equity incentive plan share pools will all be proportionately recalibrated to reflect fewer outstanding shares at a higher per-share price point.
On April 22, 2026, Cue Biopharma filed a Certificate of Amendment in Delaware to implement a 1-for-30 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on April 23, 2026. The reverse split, aimed at regaining compliance with Nasdaq’s minimum bid price requirement, will consolidate every thirty shares into one, compensate fractional holdings in cash, and result in post-split trading beginning April 24, 2026 under the existing ticker with a new CUSIP number.
The most recent analyst rating on (CUE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
The score is held back primarily by weak financial performance, driven by persistent losses and negative free cash flow. Offsetting this, technical momentum is strong (though overbought), valuation screens as low on P/E, and a positive corporate event adds incremental support via a $7.5M milestone payment.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma, Inc. is a biotechnology company focused on developing targeted biologic drugs to modulate the immune system, particularly in oncology and autoimmune diseases. The company’s common stock is listed on the Nasdaq Capital Market under the trading symbol CUE, and its capital structure is governed by a Delaware certificate of incorporation.
Average Trading Volume: 9,163,047
Technical Sentiment Signal: Hold
Current Market Cap: $82.97M
See more data about CUE stock on TipRanks’ Stock Analysis page.